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Radionuclide Imaging of Tumor Angiogenesis
Ingrid Dijkgraaf and Otto C. Boerman
Summation
Angiogenesis is a multistep process regulated by pro- and antiangiogenic factors. In order to grow and me-
tastasize, tumors need a constant supply of oxygen and nutrients. For growth beyond 1–2 mm in size, tumors are
dependent on angiogenesis. Inhibition of angiogenesis is a new cancer treatment strategy that is now widely
investigated clinically. Researchers have begun to search for objective measures that indicate pharmacologic
responses to antiangiogenic drugs. Therefore, there is a great interest in techniques to visualize angiogenesis in
growing tumors noninvasively. Several markers have been described that are preferentially expressed on newly
formed blood vessels in tumors (avb3 integrin, vascular endothelial growth factor, and its receptor, prostate-
specific membrane antigen) and in the extracellular matrix surrounding newly formed blood vessels (extra
domain B of fibronectin, Tenascin-C, matrix metalloproteinases, and Robo-4). Several ligands targeting these
markers have been tested as a radiotracer for imaging angiogenesis in tumors. The potential of some of these
tracers, such as radiolabeled cyclic RGD peptides and radiolabeled anti-PSMA antibodies, has already been
tested in cancer patients, while for markers such as Robo-4, the ligand has not yet been identified. In this review,
an overview on the currently used nuclear imaging probes for noninvasive visualization of tumor angiogenesis
is given.
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Introduction
Angiogenesis, the formation of new blood vessels fromexisting ones, is an essential process if solid tumors are to
grow beyond 2–3 mm3, since diffusion is no longer sufficient
to supply the tissue with oxygen and nutrients.1 Tumor-
induced angiogenesis is a complex, multistep process that
follows a characteristic cascade of events mediated and con-
trolled by growth factors, cellular receptors, and adhesion
molecules.2–4 In this process, five phases can be distinguished:
1) endothelial cell activation, 2) basement membrane degra-
dation, 3) endothelial cell migration, 4) vessel formation, and
5) angiogenic remodeling.5
The activation of preexisting quiescent vessels can be
triggered by hypoxia. Hypoxia induces the expression of
hypoxia-inducible factor (HIF), which binds to the hypoxic
response element. As a result, the expression of hypoxia-
inducible genes, such as vascular endothelial growth factor
(VEGF), carbonic anhydrase IX (CAIX), platelet-derived
growth factor (PDGF), and transforming growth factor-a
(TGF-a), is induced.6
Activated endothelial cells express the dimeric transmem-
brane integrin, avb3, which interacts with extracellular matrix
proteins (e.g., vitronectin, tenascin, fibronectin, and so forth)
and regulates migration of the endothelial cell through the
extracellular matrix during vessel formation.7,8 The activated
endothelial cells synthesize proteolytic enzymes, such as
matrix metalloproteinases (MMPs), used to degrade the
basement membrane and the extracellular matrix.9 Initially,
endothelial cells assemble as solid cords. Subsequently, the
inner layer of endothelial cells undergoes apoptosis, leading
to the formation of the vessel lumen. Finally, this primary,
immature vasculature undergoes extensive remodeling, dur-
ing which the vessels are stabilized by pericytes and smooth
muscle cells. This step is often incomplete in tumors, resulting
in the characteristic, increased permeability of tumor vessels.
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Based on a balance between pro- and antiangiogenic fac-
tors, a tumor can stay dormant for a very long time until the
so-called ‘‘angiogenic switch’’ occurs. In most tissues, tumors
can only grow to a life-threatening size if the tumor is able to
trigger angiogenesis. In tissues with high vessel densities
(e.g., liver, brain, and so forth), tumors may also progress via
angiogenesis-independent co-option of the preexistent vas-
culature.10
In summary, tumor-induced angiogenesis is a multistep
process and a key feature of a tumor lesion that has major
impact on the biologic behavior of the lesion. Inhibition of
angiogenesis is a new cancer treatment strategy that is now
widely investigated clinically. Researchers have begun to
search for objective measures that indicate pharmacologic re-
sponses to antiangiogenic drugs. Therefore, there is a great
interest in techniques to visualize angiogenesis in growing
tumors noninvasively. During the past decade, several mark-
ers of angiogenesis have been identified and specific tracers
targeting these markers have been developed. In this review,
an overview on the currently used nuclear imaging probes for
noninvasive visualization of tumor angiogenesis is given.
avb3 Integrin Receptor
The avb3 integrin, also referred to as the vitronectin re-
ceptor, belongs to the integrin receptors. Integrins are a
family of heterodimeric transmembrane glycoproteins that
function in cellular adhesion, migration, and signal trans-
duction. The term ‘‘integrin’’ was derived from the ability of
these proteins to link the extracellular matrix (ECM) proteins
with the intracellular cytoskeleton.11 Each member of this
family consists of two noncovalently bound transmembrane
polypeptide subunits, alpha and beta. Integrins have a large
extracellular domain, which binds extracellular ligands, a
transmembrane domain, and a relatively small intracellular
domain responsible for interaction with the cytoskeleton and
intracellular signaling pathways. To date, 18 alpha- and 8
beta-subunits have been identified, which associate selec-
tively to form at least 24 different integrins. The unique
combinations of alpha- and beta-subunits determine which
ECM ligands are recognized by a cell. Binding of ECM li-
gands to integrins triggers interactions between several sig-
naling molecules in close vicinity to the extracellular and
cytoplasmic regions of the integrin receptor.12,13 Integrin-
mediated cell adhesion may affect the cell-cycle kinetics or
may cause anchorage-dependent cell death or anoikis.14,15
The alpha-v-subunit can associate with various integrin
beta-subunits. At present, there are at least three distinct
b-subunits known, which associate with the av-subunit,
namely, b1, b3, and b5. Integrin avb3 is expressed on a variety
of cell types, including osteoclasts, vascular smooth muscle
cells, and endothelial cells. In addition, avb3 integrin is ex-
pressed on the cell membrane of various tumor cell types,
such as ovarian cancer, neuroblastoma, breast cancer, mela-
noma, and others. Further, integrin avb3 is minimally
expressed on normal quiescent endothelial cells, but signifi-
cantly upregulated on activated endothelial cells during an-
giogenesis.16 avb3 integrin expressed on endothelial cells
modulate cell migration and survival during angiogenesis,
whereas avb3 integrin expressed on carcinoma cells potenti-
ate metastasis by facilitating invasion and movement across
blood vessels.
Integrin avb3 binds extracellular matrix proteins (e.g., vi-
tronectin, fibrinogen, laminin, and collagen) through ex-
posed tripeptide arginine-glycine-aspartic acid (RGD)
amino-acid moieties.17 Several research groups have inves-
tigated the potential of RGD-containing peptides to target
avb3 expressed in tumors with radionuclides. It was found
that the cyclic pentapeptide, cyclo(Arg-Gly-Asp-d-Phe-Val),
having an IC50 value in the lower nanomolar range, was a
100-fold better inhibitor of cell adhesion to vitronectin,
compared to the linear variant.18,19 It was found that besides
the essential RGD sequence, a hydrophobic amino acid in
position 4 increases the affinity for avb3.
20 Based on this
finding, Haubner et al. designed five peptides that could be
radioiodinated by introducing a tyrosine residue. Two of
these peptides, cyclo(Arg-Gly-Asp-d-Tyr-Val) and cyclo(Arg-
Gly-Asp-d-Phe-Tyr) (designated as P1 and P4, respectively),
were studied in vivo.21 The biodistribution of the radio-
iodinated peptides was studied in nude mice with various
subcutaneous (s.c.) human tumors (M21 melanoma, MaCaF
mammary carcinoma, and osteocarcoma). The peptides
rapidly cleared from the blood; blood levels were lower than
1 %ID=g (percent injected dose per g) as early as 10 minutes
postinjection (p.i.). In the M21 melanoma model, the tumor
uptake peaked at 10 minutes p.i. (1.12 0.98 %ID=g) and
decreased to 0.12 0.04 %ID=g at 2 hours p.i. However, both
peptides cleared via the hepatobiliary route and revealed
relatively high hepatic uptake, especially at early time points
(*5 %ID=g, 1 hour p.i.). Therefore, the pharmacokinetics of
this first-generation radiohalogenated RGD peptides were
improved by conjugating them with sugar amino acids. A
glucose-based sugar amino acid (SAA1) was conjugated to
the epsilon-amino function of lysine in the pentapeptide.
Compared to the noncarbohydrated radioiodinated P4, the
resulting iodine-labeled glucopeptide, 3-[*I]iodo-d-Tyr4-
cyclo(Arg-Gly-Asp-d-Tyr-Lys (SAA1)) (*I-Gluco-RGD) showed
reduced activity accumulation in the liver, an initially in-
creased activity concentration in the blood, and an increased
uptake and retention in the tumor.22 Based on these data, a
galactose-based sugar amino acid (SAA2) was conjugated with
cyclo(Arg-Gly-Asp-d-Phe-Lys), allowing prosthetic group la-
beling.22,23 Due to the low lipophilicity of the small propionyl
moiety, 4-nitrophenyl-2-[18F]fluoropropoinate ([18F]NFP) was
used for 18F-labeling. The resulting [18F]Galacto-RGD was the
first radiotracer applied in patients.
The conjugation of the DTPA-moiety in the pentapeptide,
cyclo(Arg-Gly-Asp-d-Tyr-Lys), via the epsilon group of the
lysine residue also made the peptide more hydrophilic and
facilitated renal clearance, in contrast to the non-DTPA-
conjugated radioiodinated peptide, which is cleared pre-
dominantly via the hepatic route.24
The hydrophilicity of peptides can also be enhanced by
linking them to polyethylene glycol (PEG) chains, an ap-
proach called PEGylation. Chen et al. coupled PEG-moieties
to RGD-containing peptides. Radioiodinated, 18F-, and 64Cu-
labeled derivatives were studied and demonstrated different
effects of PEGylation on the pharmacokinetics, tumor uptake,
and retention of the RGD peptides. This could be due to the
nature of the lead structure and the size of the PEG-moiety.
For example, 125I-RGD-mPEG [mPEG molecular weight
(MW)¼ 2000] demonstrated higher activity concentration
in liver and intestines, compared to 125I-RGD. In addition,
the PEGylated analog showed faster blood clearance, lower
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tumor uptake, but improved tumor retention, compared to
125I-RGD.25 In contrast, the PEGylated RGD peptide, 64Cu-
DOTA-PEG-RGD (PEG MW¼ 3400), showed lower uptake in
liver and intestine with no effect on tumor uptake and re-
tention, compared to 64Cu-DOTA-RGD.26 A direct compari-
son in mice with s.c. U87MG glioblastoma demonstrated that
[18F]FB-PEG-RGD (PEG MW¼ 3400) had significantly im-
proved tumor retention relative to [18F]FB-RGD without
compromising hepatic and renal clearance of activity.27
Recently, a 99mTc-labeled RGD-containing peptide
(NC100692) was evaluated in ischemic models and showed
high uptake in areas of neovascularization with avb3 integrin
overexpression.28 In these models, it was shown that
NC100692 bonds to avb3-expressing endothelial cells in the
regions of angiogenesis.29
Clinical studies
As described above, [18F]Galacto-RGD was the first
radiotracer applied in patients and could successfully image
avb3 expression in human tumors with good tumor-to-
background ratios.30 Further biodistribution and dosimetry
studies confirmed rapid clearance of [18F]Galacto-RGD from
the blood pool and, primarily, renal excretion.31–33 It has
been shown that molecular imaging of avb3 expression, with
[18F]Galacto-RGD in humans correlated with avb3 expres-
sion, as determined by immunohistochemistry.34 In another
study, the tracer uptake of [18F]FDG and [18F]Galacto-RGD
in patients with non-small-cell lung cancer (NSCLC; n¼ 10)
and various other tumors (n¼ 8) was compared (Fig. 1), in-
dicating that [18F]FDG uptake in tumor lesions did not cor-
relate with [18F]Galacto-RGD uptake. These results showed
that avb3 expression and glucose metabolism are not closely
correlated in tumor lesions, and that, consequently, [18F]FDG
cannot provide similar information as [18F]Galacto-RGD.35
The second radiotracer that was applied in patients was
99mTc-NC100692. A clinical study was performed to provide
an initial indication of the efficacy and safety of imaging
malignant breast tumors.36 Nineteen (19) of 22 tumors were
detected with this radiotracer. In an additional study,
FIG. 1. [18F]FDG-PET of a patient with non-small-cell lung cancer (NSCLC) showed intense tracer uptake in the lesion (A).
PET imaging of avb3 integrin expression with [
18F]Galacto-RGD showed heterogeneous tracer uptake in the lesion, with a
different pattern, compared to the [18F]FDG-PET (B). PET=CT (C) and PET=MRI (T2w) image fusion (D) are useful for a good
correlation of anatomic and biologic information. FDG, Fluorodeoxyglucose; PET, positron emission tomography; CT,
computed tomography; MRI, magnetic resonance imaging.
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integrin scintimammography with 99mTc-NC100692, using a
dedicated g-camera, was performed to investigate the ability
to detect malignant breast cancer lesions.37 All patients were
known to have lesions highly suspicious of malignancy.
Dedicated integrin scintimammography (DISM) detected
malignant lesions in 7 of 8 patients with focal uptake in all
but 2 tumor lesions.
Multimeric RGD peptides
To improve the efficiency of tumor targeting and to obtain
better in vivo imaging properties, multimeric RGD peptides
were synthesized and characterized. The first cyclic RGD
multimers that were developed were E[c(RGDfK)]2-based
dimers (Fig. 2).38–44 Subsequently, the Stanford group re-
ported the use of E[c(RGDyK)]2-based dimers labeled with
64Cu or 18F for positron emission tomography (PET) imag-
ing.45 The dimeric RGD peptide, E(c(RGDyK))2, was la-
beled with 18F via a prosthetic 4-[18F]fluorobenzoyl moiety.46
In in vivo studies, the resulting [18F]FB-E(c(RGDyK))2
showed significantly higher tumor uptake and prolonged
tumor retention, compared with its monomeric analog,
[18F]FB-c(RGDyK). In addition, the dimeric peptide had a
predominant renal excretion, whereas the monomeric analog
was excreted preliminary through the biliary route.
The group in Munich developed the pentapeptide cyclo(-
RGDfE-) for multimerization of RGD peptides.47 In their
studies, glutamic acid was chosen as the fifth amino acid,
since it provides a free carboxylic group for peptide-coupling
reactions. cyclo(-RGDfE-), and was linked to either amino-
hexanoic acid (Ahx) or to heptaethylene glycol (HEG) as
spacer molecules. Subsequently, these monomeric units were
bridged via lysine or lysine tree to form dimeric and tetra-
meric RGD peptides. The final 18F-labeling step was carried
out by oxime ligation, for example, by using 4-[18F]fluor-
obenzaldehyde as the 18F-labeled synthon. In in vitro studies,
the multimers showed significantly increased affinity to avb3:
monomer <dimer <tetramer. For example, avb3-affinities of
the cyclo(-RGDfE-)-mono-, di-, and tetramer containing HEG
spacer units were increased by a factor of 10 with each
duplication of binding units (IC50¼ 20, 3.0, and 0.2 nM,
respectively for the mono-, di-, and tetramer). In mice with
avb3-positive M21-melanoma,
48 the tumor uptake of the 18F-
labeled RGD peptides increased in the series monomer
<dimer& tetramer, but due to lower uptake of the tetramer
in all other tissues, compared to the dimer, tumor-to-organ
ratios were highest for the 18F-labeled RGD-tetramer, leading
to a significant improved imaging.48,49
Although the potential benefits of multivalent probes are
generally accepted, the exact mechanism of the enhanced
accumulation in avb3-expressing tumors is not exactly clear. It
is unlikely that these multimers bind several avb3 integrins
simultaneously, because the distance between the RGD units
is very short. Statistical rebinding is the most likely expla-
nation for the enhanced affinity of the multimers, compared
to their monomeric counterparts. Due to the incorporation of
Ahx- or HEG-spacers, the distance between the cyclo(RGDfE)
moieties might be long enough to bind adjacent avb3 integrins
simultaneously and thus multivalently. Recently, Liu et al.
extended the distance between two RGD motifs by PEG4
linkers, resulting in a higher affinity and a significantly higher
tumor uptake, compared with the dimer without linkers.50
During recent years, various other RGD dimers, tetramers,
and even octamers labeled with different radionuclides have
been developed and studied in vitro and in vivo.51–59 Gen-
erally, the results from several research groups have dem-
onstrated that increasing the peptide multiplicity can
significantly enhance the integrin avb3-binding affinity of
RGD peptides and improve tumor-targeting capability of the
radiotracer (Fig. 3).60 In addition, the incorporation of the
right spacer between the RGD motifs can enhance the affinity
FIG. 2. Tumor uptake of 111In-DOTA-E-c(RGDfK), 111In-
DOTA-E-[c(RGDfK)]2, and
111In-DOTA-E{E[c(RGDfK)]2}2 at
2, 8, and 24 hours after injection in athymic mice with sub-
cutaneous SK-RC-52 tumors. Results are reflected as mean
injected dose per gram standard deviation. Values were
analyzed by using one-way analysis of variance. *p< 0.05;
**p< 0.01; #p< 0.05; ##p< 0.01. p-values refer to differences
in tumor uptake between 111In-DOTA-E-c(RGDfK) and 111In-
DOTA-E-[c(RGDfK)]2 or differences in tumor uptake be-
tween 111In-DOTA-E-[c(RGDfK)]2 and
111In-DOTA-E{E[c
(RGDfK)]2}2.
FIG. 3. Tumor-to-blood ratios of 111In-DOTA-E-c(RGDfK),
111In-DOTA-E-[c(RGDfK)]2, and
111In-DOTA-E{E[c(RGDfK)]2}2
at 2, 8, and 24 hours after injection in athymic mice with
subcutaneous SK-RC-52 tumors. Each bar represents the
mean values standard deviation. Values were analyzed by
using one-way analysis of variance. *p< 0.05.
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for avb3 and improve the tumor uptake. Among mono-, di-,
tetra-, and octameric cyclo(RGDfK)-based peptides, the oc-
tamer had the highest avb3 affinity and, usually, the highest
tumor uptake. From this point of view, further increase of
RGD peptide multiplicity may result in the formation of
oligo- or polymeric cyclic RGD peptides with improved in-
tegrin avb3-binding affinity and tumor targeting efficacy.
Integrin a5b1
The a5b1 integrin, also known as very late antigen-5 (VLA-
5, fibronectin receptor), is the only integrin heterodimer that
contains the a5-subunit.
61–63 This integrin functions as a re-
ceptor for fibronectin and certain other ECM proteins.62 In-
tegrin a5b1 is poorly expressed on quiescent endothelium,
but its expression is significantly upregulated on endothe-
lium during tumor angiogenesis in both mice and humans.64
a5b1-binding ligands are currently under development.
Radiolabeled high-affinity a5b1-binders might be more se-
lective tracers to image angiogenic processes in animal
models and patients than avb3-binding tracers.
VEGF Receptors
VEGF is a key regulator of angiogenesis during embryo-
genesis, skeletal growth, and reproductive functions. The
expression of VEGF is upregulated by environmental stress
caused by hypoxia, anemia, myocardial ischemia, and tu-
mor progression to initiate neovascularization.65 Via alter-
native mRNA splicing, the human VEGF-A gene gives rise to
four isoforms having 121, 165, 189, and 206 amino acids
(VEGF121, VEGF165, VEGF189, and VEGF206, respective-
ly).66,67 Less-frequent splice variants have been identified
more recently, including VEGF145,
68 VEGF183,
69 VEGF162,
70
and VEGF165b.
71 The VEGF isoforms differ not only in their
molecular mass, but also in their solubility and receptor-
binding characteristics.
Initially, VEGF receptors were identified on the cell sur-
face of vascular endothelial cells in vitro72,73 and in vivo.74,75
Subsequently, it was demonstrated that receptors for VEGF
also occur on bone-marrow–derived cells, such as mono-
cytes.76 VEGF binds two related receptor tyrosine kinases
(RTKs), VEGFR-1 and VEGFR-2. Both receptors consist of
seven Ig-like domains in the extracellular domain, a single
transmembrane region, and a consensus tyrosine kinase se-
quence that is interrupted by a kinase-insert domain.77–79
VEGFR-1 binds VEGF with a higher affinity, compared to
VEGFR-2 (Kd: 25 versus 75–250 pM).
80–82 VEGFR-1 is con-
sidered to be a decoy receptor and VEGF-A only signals
through VEGFR-2.83
Bevacizumab is a humanized variant of the anti-VEGF-A
monoclonal antibody (mAb), A.4.6.1. It is directed against a
common epitope encoded by exon 4, present on all VEGF-
isoforms, and prevents interaction with VEGFR-1 and
VEGFR-2.84 Nagengast et al. were the first to demonstrate
noninvasive VEGF imaging from using radiolabeled bev-
acizumab. In their study, they demonstrated the potential of
89Zr- and 111In-bevacizumab as a specific VEGF tracer in
nude mice with human SKOV-3 ovarian tumor xenografts.85
At the same time, our group showed specific imaging of
VEGF-A expression from using 111In-bevacizumab in mice
with s.c. human colon carcinoma xenografts LS174T (Fig. 4).86
We were the first to investigate the potential of 111In-labeled
bevacizumab to image the expression of VEGF-A in tumors
in cancer patients. In a study in colorectal cancer patients
with liver metastases, the liver metastases in 9 of 12 patients
were visualized with 111In-bevacizumab. In this study, the
liver metastases were resected after scintigraphic imaging,
allowing further immunohistochemical analysis. The VEGF-
A expression in these resected liver metastases was de-
termined by in situ hybridization and by enzyme-linked
immunosorbent assay (ELISA). Surprisingly, no correlation
was found between the level of antibody accumulation and
expression of VEGF-A.
Cai et al. labeled VEGF121 with
64Cu via DOTA for PET
imaging of VEGFR expression.87 Small-animal PET imaging
revealed rapid, specific, and prominent uptake of 64Cu-DOTA-
VEGF121 in highly vascularized small U87MG human glio-
blastoma tumors (high VEGFR expression), but significantly
lower uptake in large U87MG tumors (low VEGFR expression).
Matrix Metalloproteinases
Matrix metalloproteinases (MMPs) are a family of more than
20 extracellular proteins, which are able to degrade structural
components of the extracellular matrix (ECM) and basement
membranes with overlapping substrate specificity.88–90 MMPs
are zinc- and calcium-dependent secreted or membrane-
anchored endopeptidases. They play a role in several physiologic
processes, including angiogenesis, embryonic development,
tissue morphogenesis, and wound healing. However,
FIG. 4. Scintigraphic images of 3 athymic male mice with subcutaneous LS174T tumors immediately after injection and at 1,
3, and 7 days postinjection of 111In-bevacizumab (0.9 MBq=mouse, 3 mg=mouse).
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MMP expression and activity are upregulated under many
pathologic conditions, such as atherosclerosis, inflammatory
processes, and angiogenesis in tumors.91,92 In epithelial tu-
mors, most of the upregulated MMPs are expressed by the host
stromal cells.93 Expression of MMPs is associated with the
removal of the ECM barrier to allow cancer cells and endo-
thelial cells to invade the tissue. A number of MMPs are spe-
cifically involved in angiogenesis, including MMPs 1, 2, 3, 9,
and 14. There is a growing interest in the use of radiolabeled
MMP ligands as tracers to image angiogenesis in tumors and
their potential to metastasize possibly.94–96
Using phage display libraries, Koivunen et al. found that
cyclo(Cys-Thr-Thr-His-Trp-Gly-Phe-Thr-Leu-Cys) (CTT), a
disulfide-bridged decapeptide, selectively inhibited MMP2
and 9.97 CTT reduced the migration of both human endo-
thelial and tumor cells and prevented tumor growth and
invasion in animal models. The Munich group derivatized,
radioiodinated, and evaluated CTT as a tracer for imaging
MMP2 and 9 activity. In in vivo studies, CTT demonstrated
high lipophilicity, resulting in high liver and kidney uptake.
In addition, this peptide showed low tumor uptake due to
the poor stability of the 125I-d-Tyr-modified peptide. In an-
other study, CTT was conjugated to the chelator, DOTA, for
radiolabeling with 64Cu and subsequent microPET imaging
of MMP2=9-expressing tumors.98 Although there was some
evidence for selective uptake of 64Cu-DOTA-CTT by MMP2-
and MMP9-expressing tumors, this tracer had a low affinity
for MMP2 and MMP-9 and showed low accumulation in
tumors.
The above-mentioned radiotracers are based on the ap-
plication of peptides for the imaging of activated MMPs.
Another approach is based on the use of small-molecule
nonpeptidyl matrix metalloproteinase inhibitors (MMPIs).
These nonpeptidyl tracers for MMP imaging were reviewed
recently.99 The N-sulfonyl amino acid hydroxamates, CGS
25966 and CGS 27023A, appeared to be prominent lead
structures for potential radiolabeled tracers. These lead
compounds inhibit MMP1, 2, 3, and 9 by chelating the zinc
ion of the enzyme active site with the hydroxamic acid
moiety.100,101 Lately, the 123I-labeled CGS 27023A-derivative
[123I]I-HO-CGS 27023A has been synthesized and was tested
in vitro and in vivo. This radiotracer specifically visualized
activated MMPs in vascular lesions developing after carotid
artery ligation in apolipoprotein E-deficient (ApoE=) mice
by means of planar scintigraphy.102,103 Then, research groups
focused on the development of several PET-compatible,
mainly 11C- and 18F-labeled, CGS 25966 and CGS 27023A
derivatives.104–107 Preclinical evaluation of these tracers was
either not successful108 or not published.104,105
Recently, novel fluorinated MMPIs, based on the lead
structures, CGS 25966 and CGS 27023A, were synthesized
and the inhibition potencies of the compounds were evalu-
ated in in vitro MMP inhibition assays for MMP2, 8, 9, and
13. With the exception of one compound, all fluorinated
hydroxamates are still potent, broad-spectrum MMPIs
(IC50¼ 0.5–527 nM). Subsequent biodistribution and me-
tabolism studies of two radioligands ([18F]1f and [18F]1j) in
wild-type (WT) mice demonstrated no tissue-specific accu-
mulation, which may be an advantage in the study of acti-
vated and dysregulated MMPs. This new class of
hydroxamate-based radioligands could evolve into tracers
for noninvasive detection of activated MMPs.
Prostate-Specific Membrane Antigen
Prostate-specific membrane antigen (PSMA) is a trans-
membrane protein that is overexpressed in prostate cancer.
The anti-PSMA antibody, capromab pendetide, labeled with
111In, is marketed as ProstaScint, a U.S. Food and Drug
Administered (FDA)-approved antibody preparation for the
detection of nodal metastases in prostate cancer patients.109
However, this antibody is directed against an intracellular
epitope of PSMA, which is considered a suboptimal target
for antibody imaging. PSMA was also found to be expressed
on the neovascular endothelium of most solid tumor types,
while there is no expression on the endothelial cells of nor-
mal tissue.110
J591 is a mAb directed against an epitope on the extra-
cellular domain of PSMA.111 Previous studies have shown
that J591 accumulated in metastatic prostate cancer le-
sions.112 In a recent phase I trial, the feasibility of targeting
the neovasculature of a wide range of adenocarcinomas,
using 111In-labeled humanized J591, was investigated. Pa-
tients with melanoma and cancers of the breast, colon, liver,
and kidney were injected with 111In-J591. In these patients
(n¼ 24) the antibody accreted in all known tumor sites. Se-
venteen (17) of 18 (94%) patients with soft tissue disease on
standard scans showed uptake in the soft tissues on antibody
scans, as did 6 of 6 patients with bone disease. These data
show selective targeting of PSMA expressed on tumor en-
dothelium.113 111In-huJ591 has the potential to become a
suitable tracer for imaging angiogenesis.
More recently, the first PET imaging agent for PSMA was
synthesized in an extension of their previous work with the
11C-labeled DCMC, which binds to the active carboxy pep-
tidase site of PSMA.114 Mease et al. synthesized an agent
containing 18F: 18F-DCFBC. 18F-DCFBC was demonstrated to
localize in PSMA-expressing tumors in mice, allowing im-
aging by small animal PET.115
ECM Proteins
A few antigens in the ECM have been identified that are
preferentially expressed in the surroundings of newly
formed blood vessels.
Extra domain B of fibronectin
Fibronectin is a large glycoprotein in the ECM. The extra
domain B (ED-B) of fibronectin is a sequence of 91 amino
acids, identical in mice, rats, and humans, that can be inserted
into the fibronectin molecule at sites of tissue remodeling by
alternative splicing. ED-B is specifically expressed around
neovascular structures in tumors and other tissues undergo-
ing angiogenesis, but is undetectable in the normal adult
tissues.116 Using phage display technology, single-chain an-
tibodies (scFv) directed against EDB have been isolated.117,118
The human single-domain antibody (scFv), L19, was shown
to have subnanomolar affinity for ED-B.119
Demartis et al. showed that radioiodinated scFv L19 se-
lectively accumulated around tumoral blood vessels in a
murine tumor model. Since the ED-B domain of fibronectin
has an identical sequence in mouse and man, they suggested
clinical utility for the scintigraphic detection of angiogenesis
in vivo.120 Two (2) years later, it was shown by scintigraphic
imaging that 123I-L19 selectively localized in tumor lesions of
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aggressive lung cancer as well as in liver metastases of co-
lorectal cancer patients.121 More recently, the amino-acid
sequence, (Gly)3-Cys-Ala, was inserted at the C-terminus of
L19, resulting in the anti-ED-B scFv, named AP39, which
could be labeled with 99mTc. The data revealed the feasibility
of targeting ED-B fibronectin with 99mTc-labeled L19 in nude
mice with s.c. teratocarcinoma tumors.122
Subsequently, a series of different L19 formats were con-
structed, including dimeric scFv, a human bivalent ‘‘small
immunoprotein’’ (SIP), and a complete human IgG. In com-
paring these different formats labeled with 125I=131I, L19-SIP
proved to be the most suitable tracer for imaging ED-B ex-
pression in tumors. In 2007, Rossin et al. described 76Br-L19-
SIP, the first PET-imaging derivative of L19, for imaging of
neovasculature in xenograft-bearing nude mice. Besides clear
tumor targeting, 76Br-L19-SIP also showed persistent activity
in blood, stomach, and several other normal organs, most
probably due to in vivo debromination.123
Extra domain C of tenascin
Tenascin is an ECM component. Tenascin-C, containing
the extra domain C, is a splice variant of tenascin. Over-
expression of this splice variant has been reported in high-
grade astrocytomas, with a prominent pattern of staining
around tumor neovasculature. In contrast, domain C was
undetectable in normal human tissues and by immuno-
histochemistry and even at the level of Northern blot
analysis.124
Recently, Silacci et al. reported that the extra domain C is
strongly expressed in the majority of lung cancers, with a
vascular and stromal pattern of expression. Using antibody
phage technology, they have generated a high-affinity
human antibody fragment (G11), which was shown to se-
lectively target tenascin-C in s.c. U87 gliomas in mice.125
These results pave the way for the clinical development of
the G11 antibody for imaging angiogenesis.
Magic Roundabout (Robo-4)
Magic roundabout (Robo-4) is the fourth recently identified
member of the roundabout receptor family.126 Robo-1–3 are
highly expressed in the nervous system and are involved in
axon guidance.127 The specificity of Robo-4 expression,
however, is unique, compared with the other three members;
it is highly expressed in embryonic vasculature, but not in the
nervous system.128 Robo-4 induces endothelial migration and
regulates angiogenesis. Some reports suggest that Robo-4 is
expressed exclusively in tumor neovascular endothelium, and
currently, Robo-4 is considered a highly specific marker of
tumor endothelium.129 The ligand of Robo-4 has not been
identified yet. It does not bind to slit2, the common ligand of
Robo-1–3.130 Further studies are needed to identify the li-
gands of Robo-4. Based on these ligand(s), a tracer could be
developed that can image the expression of Robo-4 in tumors.
Conclusions
Clinical trials of antiangiogenic drugs are challenging be-
cause there is no established method to monitor the effect of
these drugs. It has been suggested that the maximum toler-
ated dose of antiangiogenic drugs is not necessarily the most
effective.131 Establishing the optimal dose of an anti-
angiogenic agent, based on tumor-size measurements or on
time to disease progression, may take months or years.132
Further, in patients, tumors typically develop resistance to
antiangiogenic drugs after 6–12 months of treatment.133 Sur-
rogate markers of angiogenesis are considered to be useful not
only for the stratification of patients for treatment with anti-
angiogenic drugs, but also to determine optimal dosing, early
clinical benefit, and the development of resistance. Bio-
markers could also become essential to justify the costs of
targeted therapies by increasing the likelihood of benefit to a
level that is acceptable to patients and clinicians.
Numerous markers of tumor vasculature have been
identified, but only a few radiotracers of angiogenesis have
been tested clinically. The most extensively studied marker
of angiogenesis is the integrin, avb3. For this marker, the
single-photon emission computed tomography-tracer, 99mTc-
NC100692, and the PET tracer, 18F-galacto-RGD, have been
successfully tested in humans.
Other targets exclusively expressed on activated endo-
thelial cells may eventually be better targets for imaging
angiogenesis. Of the identified markers, PSMA, Robo-4, and
a5b1 seem to be specifically expressed on tumor neovascu-
lature.
In conclusion, a few radiotracers for imaging angiogenesis
in tumors have been tested in humans. The role of these
tracers in assessing the response to antiangiogenic therapies
has yet to be assessed.
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